Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cartesian Therapeutics (RNAC) Preferred Dividend Payments: 2014-2016

Historic Preferred Dividend Payments for Cartesian Therapeutics (RNAC) over the last 3 years, with Dec 2016 value amounting to $4.6 million.

  • Cartesian Therapeutics' Preferred Dividend Payments rose 37.55% to -$2.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$2.3 million, marking a year-over-year decrease of 183.03%. This contributed to the annual value of $4.6 million for FY2016, which is 37.75% down from last year.
  • Latest data reveals that Cartesian Therapeutics reported Preferred Dividend Payments of $4.6 million as of FY2016, which was down 37.75% from $7.3 million recorded in FY2015.
  • In the past 5 years, Cartesian Therapeutics' Preferred Dividend Payments ranged from a high of $7.3 million in FY2015 and a low of $4.6 million during FY2016.
  • For the 3-year period, Cartesian Therapeutics' Preferred Dividend Payments averaged around $5.6 million, with its median value being $5.0 million (2014).
  • In the last 5 years, Cartesian Therapeutics' Preferred Dividend Payments skyrocketed by 48.15% in 2015 and then tumbled by 37.75% in 2016.
  • Over the past 3 years, Cartesian Therapeutics' Preferred Dividend Payments (Yearly) stood at $5.0 million in 2014, then spiked by 48.15% to $7.3 million in 2015, then plummeted by 37.75% to $4.6 million in 2016.